In a patient with severe mitral regurgitation, is the MitraClip transcatheter edge‑to‑edge repair device indicated instead of the Watchman left atrial appendage occlusion device?

MitraClip vs Watchman Device: These Are NOT Alternatives

The MitraClip and Watchman devices treat completely different conditions and are not interchangeable options—MitraClip treats severe mitral regurgitation while Watchman prevents stroke in atrial fibrillation by occluding the left atrial appendage. This is not an "either/or" decision; many patients actually need BOTH devices.

Understanding the Fundamental Difference

MitraClip (Mitral Transcatheter Edge-to-Edge Repair)

• Indication: Severe symptomatic mitral regurgitation 1
• Purpose: Reduces mitral valve leak to improve heart failure symptoms and prevent irreversible left ventricular damage
• Target population:
  • High/prohibitive surgical risk patients with primary MR
  • Select patients with secondary MR who remain symptomatic despite optimal heart failure therapy 1

Watchman (Left Atrial Appendage Occlusion)

• Indication: Atrial fibrillation with elevated stroke risk (CHA₂DS₂-VASc score) who need an alternative to long-term anticoagulation 2
• Purpose: Prevents thromboembolic stroke by sealing off the left atrial appendage where clots form in atrial fibrillation
• Target population: Patients with contraindications to anticoagulation or high bleeding risk

When Patients Need BOTH Procedures

Up to 50% of patients undergoing MitraClip have concurrent indications for left atrial appendage occlusion 3. These patients typically have:

• Severe mitral regurgitation requiring intervention AND
• Atrial fibrillation with stroke risk AND
• Contraindications or high risk for long-term anticoagulation

Combined Procedure Feasibility

Performing both MitraClip and Watchman in a single session is feasible and increasingly practiced 3, 4. The WATCH-TEER study demonstrated:

• Mean procedure time: 103.6 minutes
• Technical success: 89.5% 3
• At 45 days: 21% experienced the composite endpoint (death/stroke/major bleeding), though most events occurred post-discharge 3
• Key benefit: 71% of patients discontinued anticoagulation at 45 days (vs 20% at baseline) 3

Recent meta-analysis confirms combined M-TEER/LAAO shows similar procedural success and safety compared to M-TEER alone, though some concerns exist regarding in-hospital death, stroke, and vascular complications 4.

Clinical Decision Algorithm

Step 1: Identify the Primary Problem

• Symptomatic severe MR with heart failure → MitraClip is the consideration
• Atrial fibrillation with stroke risk → Watchman is the consideration
• Both conditions present → Evaluate for combined procedure

Step 2: For Mitral Regurgitation

Assess MitraClip candidacy 1:

• Severe symptomatic MR despite guideline-directed medical therapy
• High or prohibitive surgical risk
• For secondary MR: Must remain severely symptomatic despite optimized heart failure therapy (note: over 50% of significant SMR improves with GDMT alone 5)
• Evaluation by multidisciplinary valve team required

Step 3: For Atrial Fibrillation

Assess Watchman candidacy 2:

• CHA₂DS₂-VASc score indicating stroke risk
• Contraindication to long-term anticoagulation OR
• High bleeding risk (HAS-BLED score)
• Suitable left atrial appendage anatomy on imaging

Step 4: Combined Procedure Consideration

If both indications exist 3, 4:

• Advantage: Single transseptal puncture, one procedure, potential to discontinue anticoagulation
• Requirements: Experienced operator with both skill sets, institutional capability 2
• Patient selection: Carefully assess cumulative procedural risk—very elderly or frail patients may not tolerate combined approach 6

Critical Pitfalls to Avoid

1. Do NOT choose one device over the other—they address different pathologies
2. Do NOT assume all MR patients need MitraClip—optimize GDMT first for secondary MR, as 57.5% improve to nonsignificant MR with medical therapy alone 5
3. Do NOT perform Watchman without addressing severe symptomatic MR—the MR will continue causing heart failure regardless of stroke prevention
4. Do NOT perform MitraClip without addressing anticoagulation needs—if patient has atrial fibrillation requiring anticoagulation but cannot tolerate it, consider combined approach
5. Transseptal puncture location matters—optimal site for MitraClip may differ from Watchman; this requires experienced operators 6

Post-Procedure Anticoagulation Strategy

After combined procedure, most common discharge regimen is dual antiplatelet therapy (34.2% of patients), followed by anticoagulation only (20.2%) 4. The specific regimen depends on:

• Device-specific requirements
• Bleeding risk
• Completeness of LAA seal
• Residual MR severity